Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trelegy Ellipta versus non-Ellipta multiple inhaler triple therapy in COPD usual care
NL-OMON48721Phase 4Completed
- Sponsor
- GSK
- Start
- Jun 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in COPD Assessment Test score at 24 weeks. Started Jun 2018; status: completed.
02
Drugs
fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON48721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48721.